100% agree with you in that repetition of the merger details should be presented wherever the chance arises. The more eyes the better. I feel fairly confident I can touch on some of your questions but this is all IMO only and based on the research I have conducted. Obviously, like always, everyone should do their own DD.
At this point they have every intent to continue progression of the $TPIV pipeline but I don't believe it to be nearly as important as the Marker therapies. From what I understand the large healthcare funds and research analysts aren't very high on the peptide vaccines $TPIV is developing. While Tapimmune's vaccines have shown promise many others have failed which apparently hasn't given them the best reputation. To be given any consideration by these entities we need more data, which will come. The Marker cell replacement therapies on the other hand have garnered a lot of attention. This should be obvious by the recent stock activity post merger announcement, the fact that Ted Tentoff from Piper Jaffray has joined all the calls post merger announcement, and the fact that Nomura Securities has chosen to act as advisor to Tapimmune in regard to the merger. Piper Jaffray and Nomura typically would not be involved with companies of Tapimmunes diminutive stature, at the time of the merger announcement barely pushing $30 Million market cap. These are big names and I expect coverage from Piper Jaffray, w/ a research report, to be initiated after the merger. Short answer being that Marker's cell replacement therapy is way more valuable at this point in time than Tapimmune's vaccines.
As far as the $TPIV results I believe that Q1 2019 would be the earliest we see any new data. This would be for the TPIV200 data in ovarian cancer. There is a possibility we see some data later on this year but I wouldn't hold my breath. That being said, I believe it is highly possible that the data we are supposed to see in Q1 next year will be delayed to Q2. As of the last financial report there was ~$2 million on the balance sheet. I wouldn't be surprised if they had to slow enrollment until the latest round of financing. With the addition of ~$5 million earlier this month they now have the resources to ramp it back up again. Basically what I'm saying is there is still a chance we see some data late this year or early next year but don't be surprised if it isn't until Q2 2019.
As for near term milestones I think the biggest will be the closing of this merger and with that the funding to carry the company through 2020. We should see multiple data releases over the next two years that should propel the SP higher without much risk for dilution. Probably not the answer you wanted to hear but it's what I believe based on my assumptions of when we should see $TPIV vaccine data.
As for your last question not a lot of research can be done to answer this one so again, all IMO only. I don't believe Nomura Securities would not be involved with such a tiny company under ordinary circumstances as I mentioned above. That being said, I expect they are going to make damn sure everything goes according to plan. They have already been in discussion for the next round of funding which should be the last round for quite some time. I believe the PR said this will be finalized at close of the merger so I don't expect to have any details until then. I do know that each company, $TPIV & Marker, have been valued by a neutral third party, potentially Nomura in this case, as is standard practice in these types of mergers. As we get closer we should get more SEC filings which will detail this out showing us the valuation put on both companies. I would bet the farm that Marker was valued a lot higher than $TPIV. My guess at least double but probably more, IMO only of course. Luckily these numbers will be made available so we won't have to guess. We just have to wait.
Friends don't let friends place market orders
